<?xml version="1.0" encoding="UTF-8"?>
<ref id="R7">
 <label>7</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <string-name>
    <surname>James</surname>
    <given-names>ND</given-names>
   </string-name>, 
   <string-name>
    <surname>Sydes</surname>
    <given-names>MR</given-names>
   </string-name>, 
   <string-name>
    <surname>Clarke</surname>
    <given-names>NW</given-names>
   </string-name>, 
   <etal>et al</etal>
  </person-group>. 
  <article-title>Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial</article-title>. 
  <source>Lancet</source>
  <year>2016</year>;
  <volume>387</volume>:
  <fpage>1163</fpage>â€“
  <lpage>77</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S0140-6736(15)01037-5</pub-id>
  <?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/26719232?>
  <pub-id pub-id-type="pmid">26719232</pub-id>
 </mixed-citation>
</ref>
